Purpose To evaluate the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of colorectal liver metastases. Methods Forty-two patients with inoperable colorectal liver metastases not amenable to radiofrequency ablation (RFA) were treated with SBRT for a total number of 52 lesions. All patients received a total dose of 75 Gy in 3 consecutive fractions. Mean size of the lesions was 3.5 cm (range 1.1-5.4). Toxicity was classified according to the Common Toxicity Criteria version 3.0. Results Median follow-up was 24 (range 4-47) months. The progression in field was observed in 5 lesions. Twenty-four months actuarial local control (LC) rate was 91 %. Median overall survival (OS) was 29.2 +/- 3.7 months. Actuarial OS rate at 24 months was 65 %. Median progression free survival was 12.0 +/- 4.2 months; 24 months actuarial rate was 35 %. No patients experienced radiation-induced liver disease or grade >= 3 toxicity. Conclusions SBRT represents a feasible alternative for the treatment of colorectal liver metastases not amenable to surgery or other ablative treatments in selected patients, showing optimal LC and promising survival rate. OI Scorsetti, Marta/0000-0003-0320-559X

Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer

Scorsetti M;Rimassa L;Torzilli G;Santoro A;
2015-01-01

Abstract

Purpose To evaluate the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of colorectal liver metastases. Methods Forty-two patients with inoperable colorectal liver metastases not amenable to radiofrequency ablation (RFA) were treated with SBRT for a total number of 52 lesions. All patients received a total dose of 75 Gy in 3 consecutive fractions. Mean size of the lesions was 3.5 cm (range 1.1-5.4). Toxicity was classified according to the Common Toxicity Criteria version 3.0. Results Median follow-up was 24 (range 4-47) months. The progression in field was observed in 5 lesions. Twenty-four months actuarial local control (LC) rate was 91 %. Median overall survival (OS) was 29.2 +/- 3.7 months. Actuarial OS rate at 24 months was 65 %. Median progression free survival was 12.0 +/- 4.2 months; 24 months actuarial rate was 35 %. No patients experienced radiation-induced liver disease or grade >= 3 toxicity. Conclusions SBRT represents a feasible alternative for the treatment of colorectal liver metastases not amenable to surgery or other ablative treatments in selected patients, showing optimal LC and promising survival rate. OI Scorsetti, Marta/0000-0003-0320-559X
File in questo prodotto:
File Dimensione Formato  
s00280-014-2420-1.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 191.59 kB
Formato Adobe PDF
191.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/6687
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 138
  • ???jsp.display-item.citation.isi??? 111
social impact